155 related articles for article (PubMed ID: 7308280)
21. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
[TBL] [Abstract][Full Text] [Related]
22. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Geigenberger A; Degen J; Maier-Lenz H
Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
[TBL] [Abstract][Full Text] [Related]
23. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
Rietbrock N; Knoll J; Merz PG; Menke G
Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results.
Steudel HC; Volkenandt M; Steudel AT
Z Kardiol; 1983; 72 Suppl 3():24-8. PubMed ID: 6666228
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of isosorbide dinitrate in healthy volunteers after 24-hour intravenous infusion.
Bergami A; Bernasconi R; Caccia S; Leopaldi D; Mizrahi J; Sardina M; Urso R; Warrington SJ; Latini R
J Clin Pharmacol; 1997 Sep; 37(9):828-33. PubMed ID: 9549637
[TBL] [Abstract][Full Text] [Related]
26. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
Kumagae H; Koiwaya Y; Tanaka K
Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and pharmacodynamics of isosorbide dinitrate.
Fung HL
Am Heart J; 1985 Jul; 110(1 Pt 2):213-6. PubMed ID: 4013997
[TBL] [Abstract][Full Text] [Related]
28. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man.
Johnson KI; Gladigau V; Schnelle K
Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234
[TBL] [Abstract][Full Text] [Related]
29. Influence of beta-blocker coadministration on the kinetics of isosorbide mononitrate and dinitrate.
Ochs HR; Neugebauer G; Greenblatt DJ; Labedzki L
Klin Wochenschr; 1986 Dec; 64(23):1213-6. PubMed ID: 2879959
[TBL] [Abstract][Full Text] [Related]
30. Isosorbide 5-mononitrate pharmacokinetics in humans.
Taylor T; Chasseaud LF; Major R; Doyle E; Darragh A
Biopharm Drug Dispos; 1981; 2(3):255-63. PubMed ID: 7295882
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of isosorbide mononitrate.
Abshagen UW
Am J Cardiol; 1992 Nov; 70(17):61G-66G. PubMed ID: 1449102
[TBL] [Abstract][Full Text] [Related]
32. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
Laufen H; Leitold M; Wildfeuer A
Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
[TBL] [Abstract][Full Text] [Related]
33. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.
Thomson AH; Miller SH; Green ST; Whiting B
Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048
[TBL] [Abstract][Full Text] [Related]
34. Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.
Schneider W; Menke G; Heidemann R; Satter P; Kaltenbach M; Rietbrock N
Eur J Clin Pharmacol; 1990; 38(2):145-7. PubMed ID: 2338111
[TBL] [Abstract][Full Text] [Related]
35. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
Vree TB; Dammers E; Valducci R
Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacokinetics of organic nitrates.
Bogaert MG
Clin Pharmacokinet; 1983; 8(5):410-21. PubMed ID: 6414751
[TBL] [Abstract][Full Text] [Related]
37. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
[TBL] [Abstract][Full Text] [Related]
39. Absorption and excretion of isosorbide dinitrate and isosorbide-2-mononitrate in dogs.
Cayen MN; Hicks D; Karounis J; Dvornik D
J Pharm Pharmacol; 1983 May; 35(5):312-6. PubMed ID: 6134800
[TBL] [Abstract][Full Text] [Related]
40. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
Halkin H; Almog S; Friedman E
Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
